Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

180 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized prospective study in the evaluation of the long acting GnRH antagonist Degarelix against the classical multidose regime with Ganirelix for LH suppression during the follicular phase of an ovarian stimulation cycle in oocyte donors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix

NCT03240159

Pregnancy, Ovarian

UNKNOWN PHASE3

Long Acting GnRH Antagonist in PCOS Women Undergoing IVF

NCT02084940

Polycystic Ovarian Syndrome Ovarian Hyperstimulation Syndrome Invitro Fertilization

UNKNOWN

Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix

NCT00434122

Infertility, Female

COMPLETED PHASE2

Desogestrel Versus GnRH Antagonist in IVF/ICSI

NCT04728659

IVF Infertility

UNKNOWN PHASE4

Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response and High Basal FSH

NCT00417157

Infertility Premature Ovarian Failure

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized prospective study of the use of single dose of the long acting GnRH antagonist Degarelix for ovarian stimulation cycle in oocyte donors: Ovarian stimulation started on cycle Day2 with gonadotropins 175-300 IU and either GnRH antagonist single dose Degarelix or multidose GnRH antagonist Ganirelix initiated on Day6 of the stimulation cycle. Agonist triggering was used in both groups for oocyte maturation. Blastocyst formation rate and Live Birth Rates were estimated for both groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility Premature Ovarian Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Dose antagonist Degarelix

The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with a single dose Degarelix.

live birth rate

Intervention Type DIAGNOSTIC_TEST

The blastulation rate and live birth rate according to the protocol of COS

Multidose antagonist Ganirelix

The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with multidose dose Ganirelix.

live birth rate

Intervention Type DIAGNOSTIC_TEST

The blastulation rate and live birth rate according to the protocol of COS

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

live birth rate

The blastulation rate and live birth rate according to the protocol of COS

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

blastulation rate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 20-34 years;
* body mass index (BMI) 18-29kg/m2;
* regular menstrual cycle of 26-35 days,
* AMH levels age appropriate (≥2.3 ng/ml)
* early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).

Exclusion Criteria

* women with diabetes and other metabolic disease
* women with hereditary genetic diseases;
* women with heart disease, QT prolongation,heart failure
* elevated liver enzymes, liver failure, hepatitis
* women with inflammatory or autoimmune disease
* abnormal karyotype;
* endometriosis stage III/IV;
* history of recurrent miscarriage;
* severe OHSS in a previous stimulation cycle or any contraindication for the use of gonadotrophins.

Minimum Eligible Age

20 Years

Maximum Eligible Age

34 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes